Jean-Luc M. Lemercier - Apr 6, 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role: CVP, EMEACLA and JAPAC
Signature: Linda J. Park, Attorney-in-Fact
Stock symbol: EW
Transactions as of: Apr 6, 2023
Transactions value $: -$318,060
Form type: 4
Date filed: 4/6/2023, 04:51 PM
Previous filing: Mar 8, 2023
Next filing: May 4, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EW	Common Stock	Options Exercise	$234K	+6.64K	+3.93%	$35.20	176K	Apr 6, 2023	Direct	F1
transaction	EW	Common Stock	Sale	-$552K	-6.64K	-3.78%	$83.10	169K	Apr 6, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EW	Employee Stock Option (Right to Acquire)	Options Exercise	$0	-6.64K	-50%	$0.00	6.64K	Apr 6, 2023	Common Stock	6.64K	$35.20	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022.
F2	This transaction was executed in multiple trades at prices ranging from $82.79 to $83.45 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.